Skip to content

Ocular Therapeutix, Inc.

OCUL

CIK 0001393434

← back to feed
Revenue (TTM)
$49.49M
−18.5% YoY Q1 May 2026
Net Income (TTM)
−$289.9M
−37.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.55
−16.4% YoY Q1 May 2026
Gross Margin
87.3%
Q1 May 2026
Operating Margin
-593.3%
Q1 May 2026
Net Margin
-585.8%
Q1 May 2026
Free Cash Flow (TTM)
−$174.75M
Q1 May 2026
Cash
$666.7M
Q1 May 2026
Total Debt
$18M
Q1 May 2026
Shares Outstanding
218.96M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings